Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
EMICIZUMAB-KXWH 300 MG/2 ML (150 MG/ML) SUBCUTANEOUS SOLUTION (NDC 50242093001) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved November 18, 2026 , from http://ppman.hank.ai/transparency/procedure/50242093001/by-state?code_type=NDC
“EMICIZUMAB-KXWH 300 MG/2 ML (150 MG/ML) SUBCUTANEOUS SOLUTION (NDC 50242093001) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/50242093001/by-state?code_type=NDC. Accessed
November 18, 2026 .
“EMICIZUMAB-KXWH 300 MG/2 ML (150 MG/ML) SUBCUTANEOUS SOLUTION (NDC 50242093001) by State,” HANK Price Transparency ,
accessed November 18, 2026 ,
http://ppman.hank.ai/transparency/procedure/50242093001/by-state?code_type=NDC.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
NDC · across United States
50242093001 — Emicizumab-kxwh 300 Mg/2 Ml (150 Mg/ml) Subcutaneous Solution
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$68,012
National median
$54,410 – $86,063
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 50242093001 (NDC), with interquartile range
State Median p25 p75
MI $68,012 $54,410 $86,063